PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease

Shots:

• NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate
• PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns
• PostEra will also deploy its Manifold platform, providing access to compounds through a WW network of vendors and CROs

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: LinkedIn